Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Harmony Biosciences Holdings Inc (HRMY)

Harmony Biosciences Holdings Inc (HRMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,870,046
  • Shares Outstanding, K 57,031
  • Annual Sales, $ 582,020 K
  • Annual Income, $ 128,850 K
  • EBIT $ 175 M
  • EBITDA $ 199 M
  • 60-Month Beta 0.77
  • Price/Sales 3.18
  • Price/Cash Flow 12.68
  • Price/Book 3.16

Options Overview Details

View History
  • Implied Volatility 64.23% ( +2.13%)
  • Historical Volatility 80.45%
  • IV Percentile 44%
  • IV Rank 54.17%
  • IV High 85.78% on 08/02/24
  • IV Low 38.77% on 05/20/24
  • Put/Call Vol Ratio 0.34
  • Today's Volume 59
  • Volume Avg (30-Day) 130
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 2,536
  • Open Int (30-Day) 2,205

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.64
  • Number of Estimates 3
  • High Estimate 0.74
  • Low Estimate 0.45
  • Prior Year 0.45
  • Growth Rate Est. (year over year) +42.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.02 +5.71%
on 10/31/24
41.61 -21.20%
on 10/29/24
-2.62 (-7.40%)
since 10/18/24
3-Month
31.02 +5.71%
on 10/31/24
41.61 -21.20%
on 10/29/24
-3.01 (-8.41%)
since 08/20/24
52-Week
27.14 +20.84%
on 11/21/23
41.61 -21.20%
on 10/29/24
+5.02 (+18.08%)
since 11/20/23

Most Recent Stories

More News
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript

HRMY earnings call for the period ending September 30, 2024.

HRMY : 32.79 (+0.95%)
Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript

HRMY earnings call for the period ending June 30, 2024.

HRMY : 32.79 (+0.95%)
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript

HRMY earnings call for the period ending March 31, 2024.

HRMY : 32.79 (+0.95%)
Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript

HRMY earnings call for the period ending December 31, 2023.

HRMY : 32.79 (+0.95%)
Why Harmony Biosciences Stock Got Slammed Today

The commercial-stage company was dinged by a bearish new take from a researcher.

BAC : 46.06 (-0.75%)
HRMY : 32.79 (+0.95%)
Mira Pharmaceuticals Stock Is Soaring In November... Here's Why

Leveraging a favorable DEA classification for its synthetic analog of THC, Mira Pharmaceuticals could be on an expedited pathway toward commercialization to treat several unmet neurological m

MIRA : 1.2650 (-9.64%)
CARA : 0.3050 (+1.36%)
CRBP : 16.08 (-2.90%)
HRMY : 32.79 (+0.95%)
JAZZ : 119.24 (+2.07%)
Harmony Biosciences (HRMY) Q3 2023 Earnings Call Transcript

HRMY earnings call for the period ending September 30, 2023.

HRMY : 32.79 (+0.95%)
HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS ON OCTOBER 31, 2023

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...

HRMY : 32.79 (+0.95%)
Wells Fargo, JPMorgan Chase rise; Harmony Biosciences, Belden fall, Friday, 10/13/2023

Stocks that traded heavily or had substantial price changes on Friday: Wells Fargo, JPMorgan Chase rise; Harmony Biosciences, Belden fall

WFC : 73.58 (+0.20%)
HRMY : 32.79 (+0.95%)
C : 68.28 (-0.47%)
CMTL : 3.03 (+3.59%)
DG : 73.27 (-4.22%)
UNH : 600.50 (+4.07%)
JPM : 240.78 (-0.95%)
Why Shares of Harmony Bioscience Are Falling on Friday

The company reported underwhelming phase 3 trial results for Pitolisant to treat idiopathic hypersomnia.

ZYNE : 1.3000 (+2.36%)
HRMY : 32.79 (+0.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Harmony Biosciences Holdings Inc.is a pharmaceutical company. It engages in developing and commercializing therapies for rare neurological disorders. Harmony Biosciences Holdings Inc.is based in Plymouth Meeting, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 34.77
2nd Resistance Point 34.21
1st Resistance Point 33.50
Last Price 32.79
1st Support Level 32.24
2nd Support Level 31.68
3rd Support Level 30.97

See More

52-Week High 41.61
Fibonacci 61.8% 36.08
Fibonacci 50% 34.37
Last Price 32.79
Fibonacci 38.2% 32.66
52-Week Low 27.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar